FIELD: medicine.
SUBSTANCE: what is described is an IL-31 monoclonal antibody. What is offered is a method of treating a mammal suffering an inflammatory disease in which IL-31 in involved that consists in introducing the described antibody. There are offered methods for reducing, inhibiting and minimising itching in a mammal that consist in introducing the described antibody.
EFFECT: invention extends the range of anti-inflammatory agents.
39 cl, 4 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PAIN MANAGEMENT AND NEURON TISSUE INFLAMMATION TREATMENT WITH USING IL-31 ANTAGONISTS | 2007 |
|
RU2440130C2 |
| METHOD OF TREATING INFLAMMATION IN NEURONAL TISSUE WITH USING MONOCLONAL ANTIBODY AND ITS BINDING FRAGMENT | 2007 |
|
RU2565391C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| CONSTRUCTED ANTI-TSLP ANTIBODY | 2010 |
|
RU2575039C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND APPLICATION METHODS | 2006 |
|
RU2431638C2 |
| TREATMENT OF INTERSTITIAL CYSTITIS | 2008 |
|
RU2570559C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| THERAPEUTIC AGENT FOR ITCHING | 2008 |
|
RU2541780C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
